OBJECTIVES BRAVO (British Randomized Controlled Trial of AV and VV Optimization) is a multicenter, randomized, crossover, noninferiority trial comparing echocardiographic optimization of atrioventricular (AV) and interventricular delay with a noninvasive blood pressure method.
. Finally, large, randomized, long-term studies demonstrated reductions in hospitalizations and mortality (11, 12) .
The beneficial effects of CRT stem ultimately from the changes in timing of cardiac activation.
The landmark CARE-HF (CArdiac REsynchronisation in Heart Failure) trial performed atrioventricular (AV) delay optimization after device implantation by using echocardiography. Echocardiography remains the most commonly recommended method for optimization (13, 14) . In this process the AV delay is set to maximize separation of the E and A waves on transmitral Doppler imaging. The precise AV and ventriculoventricular (VV) delays that maximize hemodynamic measurements vary among patients, perhaps because of the complexity of the disease and anatomic variations in lead position (15, 16) .
In current clinical practice, however, many patients do not undergo an echocardiographic optimization process, partly because of shortage of skilled staff time. Only 40% of physicians perform any form of optimization (13) . There was initially doubt over the benefit of optimizing CRT (17) , but there have been recent encouraging results on clinical outcomes using the AdaptivCRT algorithm (Medtronic, Minneapolis, Minnesota) (18) and methods dependent on implanted hemodynamic sensors (SonR, LivaNova, London, United Kingdom) (19) . However, each of these algorithms is limited to a single manufacturer. The ideal alternative to the time-and labor-intensive echocardiographic method, with reproducibility that can be challenging (20) , would be a manufacturerindependent and fully automatable method.
Instead of Doppler findings, an alternative target
for optimization is blood pressure, which does not require expert judgment and therefore can be automated to accelerate analysis and save resources. It is important to take steps to minimize noise, and we have therefore developed an acquisition protocol that involves taking multiple repeated measurements between the tested setting and a reference setting (16) . We have previously shown that when systolic blood pressure is used, it is most efficient to sample immediately after the change in pacemaker setting.
SEE PAGE 1417

A B B R E V I A T I O N S A N D A C R O N Y M S
This is because even if no changes are made, the pressure tends to change away from the starting value with the passage of time in response to spontaneous physiological processes. In addition, when settings are changed to improve cardiac output there is a resulting reflex fall in peripheral resistance that returns the blood pressure toward the mean, even though improvements in cardiac output remain (15) .
It is therefore better to sample blood pressure before this occurs.
The BRAVO (British Randomized Controlled Trial of AV and VV Optimization) trial tested the hypothesis that physiological optimization of AV and VV delay would be noninferior to echocardiographic optimization.
METHODS
STUDY DESIGN. The design (21) was a crossover trial that was prospective, randomized, and open with blinded evaluation of endpoints. Analysis of cardiopulmonary exercise test data, echocardiography, and blood results was performed by investigators blinded to the study arm.
Patients were recruited from 19 centers in the United Kingdom. Patients were randomly allocated to an optimization method using an online system. They were followed up for 6 months and then crossed over to the other optimization method for a further 6 months of follow-up (Figure 1 ).
INCLUSION AND EXCLUSION
CRITERIA. Study inclusion and exclusion criteria are shown in Table 1. OPTIMIZATION OF AV AND VV DELAY. We performed echocardiographic optimization of the AV delay using Doppler echocardiography of transmitral flow by using the iterative method as used in the CARE-HF trial (22) . VV delay optimization was performed by maximizing aortic outflow tract aortic Doppler measurements.
Hemodynamic optimization of AV and VV delay was performed using multibeat averages acquired through noninvasive blood pressure measured using the Finometer device (Finapres Medical Systems, Amsterdam, the Netherlands). To obtain a narrow confidence interval (CI) we used a specific algorithm (23) . This performs multiple alternations between a tested and reference AV delay and calculates the mean relative change in systolic blood pressure. It closely mirrors invasive optimization (24) . We first calculated the AV optimum, and then we determined the VV optimum at that AV delay. Some previous studies have used LV dP/ dt max as a target for maximization. The BRAVO trial used systolic blood pressure because this can be acquired noninvasively or invasively with equal precision, and it reflects the external consequences of cardiac function. We have previously shown that this method is highly reproducible (25) . Its noninvasive nature permits large numbers of replicates, which narrow the CI of the estimated optimum (26) 
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British RCT of AV and VV Optimization (BRAVO) interventricular timing should continue to be as important in AF as it is in sinus rhythm.
ENDPOINTS. The primary endpoint was objective exercise capacity defined as peak oxygen uptake on cardiopulmonary exercise testing (27 Step 1. Multiple replicate measurements of BP of tested setting against reference setting
Step 2. Average change in BP relative to reference setting plotted against VV delay
Step 3. Peak of parabolic curve selected as optimum
Peak of parabola selected as AV optimum
Relative Systolic BP (mm Hg)
This same process is also performed with AV-delays to plot an AV optimization curve: Continuous noninvasive beat-to-beat measurements are made through the Finometer (Finapres Medical Systems, Amsterdam, the Netherlands).
Multiple alternations are carried out between a tested atrioventricular (AV) or ventriculoventricular (VV) delay and reference AV or VV delay.
Blood pressures (BPs) before and after a transition in pacing state are measured as an average of 8 to 10 beats, as previously described (16) . The average change in BP is plotted against AV or VV delay to fit a curve. The peak of the curve is used to select the optimum. LV ¼ left ventricular.
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Declaration of Helsinki. The study was approved by the South West London Research Ethics Committee (3), and site-specific assessments were performed for each participating hospital. All patients gave prior written informed consent. The trial was registered with ClinicalTrials.gov (NCT01258829). STATISTICS. Distributions are described by their mean AE SD. NT-proBNP is expressed as log 10 NT-proBNP because it has a positive skew. Comparison between arms of the trial was performed by paired Student's t-test. Analysis was restricted to patients with before and after data for that variable. Differences between arms of the study are expressed as mean and 95% CI. The noninferiority margin for peak oxygen uptake (primary endpoint) was 0.75 ml/kg/min, for the Minnesota Living with Heart Failure score it was 4 points, for the 36-Item Short Form Health Survey version 2 physical component score it was 8.5, for NTproBNP it was a fall of 0.062 log units (i.e., approximately a 13% decrease), for LV end-diastolic dimension it was 2 mm, and for LV end-systolic volume it was 2 mm. p noninferiority was calculated for these variables against their respective noninferiority margins.
The study sample size was chosen to have 90% power to detect a margin of equivalence of 0.75 ml/kg/min at the 5% significance level, on the basis of a published reproducibility of 2.4 ml/kg/min (30) . On this basis, 177 participants per arm of the trial were required.
RESULTS
A total of 401 patients met the enrollment criteria and gave informed consent to participate in the BRAVO trial. Baseline characteristics are displayed in Table 2 .
Patients' flow and study withdrawals are illustrated in Figure 3 . A total of 22 patients did not undergo randomization; 379 patients were randomized, and 48 had AF.
There were 12 deaths, 7 during the echocardiographic arm and 5 during the hemodynamic arm.
Another 33 patients withdrew from the study because of deterioration in heart failure symptoms or were lost to follow-up, 14 during the echocardiographic arm and 19 during the hemodynamic arm.
Nine patients experienced adverse events unrelated to heart failure that led to withdrawal from the study. Six of these patients had device-related problems (device erosion requiring extraction or loss of LV lead capture, 1 where the settings were changed at another hospital), and 3 patients had other adverse events (1 stroke, 1 myocardial infarction, 1 aneurysm).
A further 31 patients withdrew for specific reasons that were not a deterioration in heart failure. These conditions included musculoskeletal deterioration, peripheral neuropathy, deterioration in balance, torn knee ligaments, depression, terminal cancer, leg ulcers, and stroke. A total of 39 patients completed all the study visits but were unable to complete both exercise tests. See Supplemental Table 1 
COMPARISON OF THE AV DELAY DETERMINED AS
OPTIMAL. For the atrial-sensed mode, the AV optimum defined by echocardiography averaged 122 AE 32 ms, and by hemodynamic optimization it was 133 AE 29 ms (difference of 11 ms; p < 0.0001).
COMPARISON OF VV DELAY DETERMINED AS
OPTIMAL. The VV delay identified as optimal using the hemodynamic method averaged 0 AE 22 ms, and by echocardiography it was LV first 2 AE 34 ms (difference of 2 ms; p ¼ 0.40) (Supplemental Figure 1) .
DISCUSSION
The primary endpoint of exercise capacity was noninferior to hemodynamic optimization compared with echocardiographic optimization. The secondary endpoints of LV dimensions, quality of life, and NT-proBNP were also not significantly different between the 2 methods. These findings suggest that hemodynamic optimization is an acceptable alternative to the established echocardiographic method. A potential explanation for the neutrality of the SMART-AV trial is that in many patients the optimal AV delay is close to 120 ms, a common default value set by manufacturers. In the BRAVO trial, the hemodynamic optimization yielded a sensed AV delay optimum that was within 20 ms of 120 ms in 70% of patients. For echocardiographic optimization, the figure was similar at 71% ( Figure 5 ). Because physiological responses are approximately parabolic near the optimum (34), the curve slopes are most shallow there, so small differences in AV delay near the optimum have only a relatively small effect on physiology (23) . This is reflected in the BRAVO trial. Figure 5 shows that the distribution in AV optima between the 2 methods is different, but in both cases w70% of the optima are within AE20 ms of 120 ms. It is the w30% of patients whose optimal AV delay is more than 20 ms from optimum who are likely to have the most to gain from patient individualized optimization.
The modal AV optima are slightly shorter with echocardiographic than with hemodynamic optimization. However, the difference is small, at 40 ms. Because this occurs at the shallow portion of the AV delay optimization curve, this difference will produce only relatively small changes in cardiac output. These small differences in cardiac output are unlikely to be detected with the clinical outcome measures we used in this study. Hemodynamic optimization using beat-to-beat noninvasive blood pressure was noninferior to the conventional established method of echocardiographic optimization. DVO 2max ¼ change in peak oxygen uptake. Log 10 NT-proBNP, log 10 pg/ml 2.8 0.6 2.8 0.6 0 262 *Scores (with SD) are listed for all the primary and secondary outcomes measures for the study following 6 months of randomization in each arm. Hemodynamic optimizations were performed at a higher heart rate using atrial pacing rather than using atrial sensing, to improve signal-to-noise ratio. Rather than performing an optimization during atrial sensing, we programmed the sensed AV delay 60 ms shorter than the AV delay identified as optimal during atrial pacing. It is possible that we would have identified a different optimal-sensed AV delay had we performed optimization during atrial sensing. However, using this protocol we found hemodynamic optimization to be noninferior to echocardiographic optimization. The relatively long duration of participation in the study, compared with other CRT studies, may explain the high frequency of dropout. The most common reason for dropout was an inability to carry out exercise testing for noncardiac reasons. Despite the high dropout rate, the study still met the predefined noninferiority threshold. This was because the midpoint value of the result was so close to neutral that the outer limit of the CI was well away from the noninferiority threshold.
This was a heterogeneous, "real-world" group of patients with heart failure who came from a In approximately one-third of patients, the optimal atrioventricular (AV) delay was found to be more than 40 ms longer or shorter than the commonly used nominal setting of 120 ms. These patients are likely to have the most to gain from AV delay optimization.
Whinnett et al. were performed only at a resting heart rate because this is the conventional method described for standard echocardiographic optimization.
CONCLUSIONS
The BRAVO trial demonstrates that the physio- TRANSLATIONAL OUTLOOK: This study did not set out to determine whether hemodynamic optimization confers an additional prognostic benefit. A much larger study would be required to determine this, and it is an area for further study. KEY WORDS biventricular pacing, cardiac resynchronization therapy, echocardiographic optimization, heart failure, hemodynamic optimization, optimization APPENDIX For a supplemental figure and tables, please see the online version of this paper.
